News

TB Trial Demonstrates Non-Inferiority of 4-Month Regimen for DS-TB Patients


22 Oct 2020
by Working Group

On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC)  announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin, pyrazinamide, and isoniazid that they concluded was non-inferior to the standard 6-month HRZE course of therapy for drug-sensitive TB patients. Study 31 was an international, randomized, controlled trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) and was conducted in collaboration with the AIDS Clinical Trials Group (ACTG). The trial contained over 2,500 participants, including 214 individuals with HIV, in 34 clinical sites in over 13 countries.

Study 31/A5349 examined the efficacy and safety of two four-month regimens with high-dose rifapentine with or without moxifloxacin for the treatment of drug-susceptible TB disease. These were compared with the existing six-month regimen (2RHZE/4RH), which includes eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol and 18 weeks of daily treatment with rifampin and isoniazid.

For more information, view the press release on the CDC website. 

More News
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...